Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions
WASHINGTON, April 14
WASHINGTON, April 14 (Reuters) - Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.
The deal, which is valued at $640 million, will allow Akorn to expand its eye drug portfolio to oral liquids and ointments.
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- U.S. court rulings create new uncertainty over Obamacare
- Israel pounds Gaza despite international peace efforts |
- EU readies possible capital, tech sanctions on Russia
- Train carrying MH17 bodies on final journey reaches Ukraine city |